NAV

Palmitoyl tetrapeptide-7

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Palmitoyl tetrapeptide-7
DrugBank Accession Number
DB14137
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Similar Structures
Weight
Average: 694.919
Monoisotopic: 694.474146368
Chemical Formula
C34H62N8O7
Synonyms
  • N-Palmitoylrigin
  • Palmitoyl-GQPR
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Buddate Reges Intensive TreatmentPalmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL)CreamTopicalBuddate Co Ltd2017-01-01Not applicableUS flag
Buddate Reges Intensive TreatmentPalmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL)CreamTopicalBuddate Co Ltd2017-01-012017-01-02US flag
Derma Under EyePalmitoyl tetrapeptide-7 (0.00015 mg/15g) + Hyaluronic acid (0.15 mg/15g) + Palmitoyl oligopeptide (0.0003 mg/15g)GelTopicalPella Pharmaceuticals Co. ltd2014-12-24Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Buddate Reges Intensive TreatmentPalmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL)CreamTopicalBuddate Co Ltd2017-01-01Not applicableUS flag
Buddate Reges Intensive TreatmentPalmitoyl tetrapeptide-7 (0.000006 g/100mL) + Butylene glycol (5.57 g/100mL) + Hydrogenated coconut oil (4 g/100mL) + Palmitoyl oligopeptide (0.000006 g/100mL) + Shea butter (3 g/100mL)CreamTopicalBuddate Co Ltd2017-01-012017-01-02US flag
Derma Under EyePalmitoyl tetrapeptide-7 (0.00015 mg/15g) + Hyaluronic acid (0.15 mg/15g) + Palmitoyl oligopeptide (0.0003 mg/15g)GelTopicalPella Pharmaceuticals Co. ltd2014-12-24Not applicableUS flag

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / Heterocyclic fatty acids / N-acyl amines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Guanidines
show 9 more
Substituents
Aliphatic heteromonocyclic compound / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Azacycle / Carbonyl group / Carboxamide group / Carboximidamide / Carboxylic acid / Fatty acid
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Q41S464P1R
CAS number
221227-05-0
InChI Key
IHRKJQSLKLYWBQ-QKDODKLFSA-N
InChI
InChI=1S/C34H62N8O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-29(44)39-24-30(45)40-25(20-21-28(35)43)32(47)42-23-16-18-27(42)31(46)41-26(33(48)49)17-15-22-38-34(36)37/h25-27H,2-24H2,1H3,(H2,35,43)(H,39,44)(H,40,45)(H,41,46)(H,48,49)(H4,36,37,38)/t25-,26-,27-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(2S)-4-carbamoyl-2-(2-hexadecanamidoacetamido)butanoyl]pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoic acid
SMILES
[H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O

References

General References
Not Available
ChemSpider
8253946
RxNav
1314277
ZINC
ZINC000163851498

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CreamTopical
GelTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00556 mg/mLALOGPS
logP2.8ALOGPS
logP0.045Chemaxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.54Chemaxon
pKa (Strongest Basic)11.23Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count10Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area252.4 Å2Chemaxon
Rotatable Bond Count28Chemaxon
Refractivity185.21 m3·mol-1Chemaxon
Polarizability79.54 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-1000219000-5c33478caf299df579e7
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-002f-0001209000-e30f5e2ceaaa4eeb89aa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004m-5113639000-87464cb6c7d6b6c8e712
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00b9-0233009000-cf9e1765996c6a1c6059
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9202320000-401c8fe8bf470bf411c7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9323102000-ad5878ed560ab7efa6c8
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-307.6530316
predicted
DarkChem Lite v0.1.0
[M+H]+308.4577316
predicted
DarkChem Lite v0.1.0
[M+Na]+306.7665316
predicted
DarkChem Lite v0.1.0

Drug created at June 27, 2018 17:28 / Updated at June 12, 2020 16:53